The angiotensin converting enzyme inhibitor captopril protects nigrostriatal dopamine neurons in animal models of parkinsonism

Experimental Neurology

Volumn 250, Issue , 2013, Pages 376-383

  Sonsalla, Patricia K ^a   Coleman, Christal ^a   Wong, Lai Yoong ^a   Harris, Suzan L ^a   Richardson, Jason R ^a   Gadad, Bharathi S ^b   Li, Wenhao ^b   German, Dwight C ^b  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Angiotensin converting enzyme; Captopril; Dopamine neurodegeneration; Mice; Microglia; MPP+; MPTP; Osmotic minipump; Parkinson's disease; Rats

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROTECTION; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DRUG EFFECT; MALE; MICROGLIA; MOUSE; NERVE CELL DEGENERATION; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; SUBSTANTIA NIGRA;

ANGIOTENSIN CONVERTING ENZYME; CAPTOPRIL; DOPAMINE NEURODEGENERATION; MICE; MICROGLIA; MPP+; MPTP; OSMOTIC MINIPUMP; PARKINSON'S DISEASE; RATS;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BRAIN; CAPTOPRIL; DOPAMINERGIC NEURONS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MPTP POISONING; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; RATS;

EID: 84887551645     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2013.10.014     Document Type: Article

References (63)

1. Albers D.S., Zeevalk G.D., Sonsalla P.K. Damage to dopaminergic nerve terminals in mice by combined treatment of intrastriatal malonate with systemic methamphetamine or MPTP. Brain Res. 1996, 718:217-220.
2. Appel S.H., Beers D.R., Henkel J.S. T cell-microglial dialogue in Parkinson's disease and amyotrophic lateral sclerosis: are we listening?. Trends Immunol. 2009, 31:7-17.
3. Arregui A., Barer G.R. Chronic hypoxia in rats: alterations of striato-nigral angiotensin converting enzyme, GABA, and glutamic acid decarboxylase. J. Neurochem. 1980, 34:740-743.
4. Benicky J., Sanchez-Lemus E., Pavel J., Saavedra J.M. Anti-inflammatory effects of angiotensin receptor blockers in the brain and the periphery. Cell. Mol. Neurobiol. 2009, 29:781-792.
5. Bernstein K.E., Ong F.S., Blackwell W.-L.B., Shah K.H., Giani J.F., Gonzalez-Villalobos R.A., Shen X.Z., Fuchs S. A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme. Pharmacol. Rev. 2013, 65:1-46.
6. Block M.L., Li G., Qin L., Wu X., Pei Z., Wang T., Wilson B., Yang J., Hong J.S. Potent regulation of microglia-derived oxidative stress and dopaminergic neuron survival: substance P vs. dynorphin. FASEB J. 2006, 20:251-258.
7. Carta A.R., Kachroo A., Schintu N., Xu K., Schwarzschild M.A., Wardas J., Morelli M. Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease. J. Neurochem. 2009, 111:1478-1489.
8. Coleman C.G., Wang G., Faraco G., Marques Lopes J., Waters E.M., Milner T.A., Iadecola C., Pickel V.M. Membrane trafficking of NADPH oxidase p47(phox) in paraventricular hypothalamic neurons parallels local free radical production in angiotensin II slow-pressor hypertension. J. Neurosci. 2013, 33:4308-4316.
9. Dehmer T., Lindenau J., Haid S., Dichgans J., Schulz J.B. Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J. Neurochem. 2000, 74:2213-2216.
10. Dikalov S. Cross talk between mitochondria and NADPH oxidases. Free Radic. Biol. Med. 2011, 51:1289-1301.
11. Dwoskin L.P., Jewell A.L., Cassis L.A. DuP 753, a nonpeptide angiotensin II-1 receptor antagonist, alters dopaminergic function in rat striatum. Naunyn Schmiedebergs Arch. Pharmacol. 1992, 345:153-159.
12. Garrido A.M., Griendling K.K. NADPH oxidases and angiotensin II receptor signaling. Mol. Cell. Endocrinol. 2009, 302:148-158.
13. Garrido P., Velenauela R., Villar-Cheda B., Lanciego J.L., Labandeira-Garcia J.L. Expression of angiotensinogen and receptors for angiotensin and prorenin in the monkey and human susbstantia nigra: an intracellular renin-angiotensin system in the nigra. Brain Struct. Funct. 2013, 218:373-388.
14. Garrido-Gil P., Joglar B., Rodriguez-Perez A.I., Guerra M.J., Labandeira-Garcia J.L. Involvement of PPAR- in the neuroprotective and anti-inflammatory effects of angiotensin type 1 receptor inhibition: effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson's disease. J. Neuroinflammation 2012, 9:38.
15. German D.C., Manaye K.F. Midbrain dopaminergic neurons (nuclei A8, A9, and A10): three-dimensional reconstruction in the rat. J. Comp. Neurol. 1993, 331:297-309.
16. German D.C., Nelson E.L., Liang C.L., Speciale S.G., Sinton C.M., Sonsalla P.K. The neurotoxin MPTP causes degeneration of specific nucleus A8, A9 and A10 dopaminergic neurons in the mouse. Neurodegeneration 1996, 5:299-312.
17. German D.C., Eagar T., Sonsalla P. Parkinson's disease: A role for the immune system. Curr. Mol. Pharmacol. 2012, 5:340-349.
18. Giovanni A., Sieber B.A., Heikkila R.E., Sonsalla P.K. Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice. J. Pharmacol. Exp. Ther. 1991, 257:691-697.
19. Giovanni A., Sieber B.A., Heikkila R.E., Sonsalla P.K. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 1: systemic administration. J. Pharmacol. Exp. Ther. 1994, 270:1000-1007.
20. Grammatopoulos T.N., Jones S.M., Ahmadi F.A., Hoover B.R., Snell L.D., Skoch J., Jhaveri V.V., Poczobutt A.M., Weyhenmeyer J.A., Zawada W.M. Angiotensin type I receptor antagonist losartan, reduces MPTP-induced degeneration of dopaminergic neurons in substantia nigra. Mol. Neurodegener. 2007, 2.
21. Hernandes M.S., Britto L.R.G. NADPH Oxidase and Neurodegeneration. Curr. Neuropharmacol. 2012, 10:321-327.
22. Hilal-Dandan R. Renin and Angiotensin. Goodman & Gillman's The Pharmacological Basis of Therapeutics, 12e 2011, McGraw-Hill, New York. L.L. Brunton, B.S. Chapner, B.C. Knollmann (Eds.).
23. Hirsch E.C., Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurol. 2009, 8:382-397.
24. Jenkins T.A., Allen A.M., Chai S.Y., MacGregor D.P., Paxinos G., Mendelsohn F.A. Interactions of angiotensin II with central dopamine. Adv. Exp. Med. Biol. 1996, 396:93-103.
25. Jenkins T.A., Wong J.Y., Howells D.W., Mendelsohn F.A., Chai S.Y. Effect of chronic angiotensin-converting enzyme inhibition on striatal dopamine content in the MPTP-treated mouse. J. Neurochem. 1999, 73:214-219.
26. Joglar B., Rodriguez-Pallares J., Rodriguez-Perez A.I., Rey P., Guerra M.J., Labandeira-Garcia J.L. The inflammatory response in the MPTP model of Parkinson's disease is mediated by brain angiotensin: relevance to progression of the disease. J. Neurochem. 2009, 109:656-669.
27. Kim-Han J.S., Antenor-Dorsey J.A., O'Malley K.L. The parkinsonian mimetic, MPP+, specifically impairs mitochondrial transport in dopamine axons. J. Neurosci. 2011, 31:7212-7221.
28. Konings C.H., Kuiper M.A., Bergmans P.L., Grijpma A.M., van Kamp G.J., Wolters E.C. Increased angiotensin-converting enzyme activity in cerebrospinal fluid of treated patients with Parkinson's disease. Clin. Chim. Acta 1994, 231:101-106.
29. Kurosaki R., Muramatsu Y., Imai Y., Kato H., Araki T. Neuroprotective effect of the angiotensin-converting enzyme inhibitor perindopril in MPTP-treated mice. Neurol. Res. 2004, 26:644-657.
30. Labandeira-Garcia J.L., Rodriguez-Pallares J., Rodriguez-Perez A.I., Garrido-Gil P., Villar-Cheda B., Valenzuela R., Guerra M.J. Brain angiotensin and dopaminergic degeneration: relevance to Parkinson's disease. Am. J. Neurodegener. Dis. 2012, 1:226-244.
31. Liang C.L., Sinton C.M., Sonsalla P.K., German D.C. Midbrain dopaminergic neurons in the mouse that contain calbindin-D28k exhibit reduced vulnerability to MPTP-induced neurodegeneration. Neurodegeneration 1996, 5:313-318.
32. Lin J.J., Yueh K.C., Chang D.C., Lin S.Z. Association between genetic polymorphism of angiotensin-converting enzyme gene and Parkinson's disease. J. Neurol. Sci. 2002, 199:25-29.
33. Lin J.J., Yueh K.C., Lin S.Z., Harn H.J., Liu J.T. Genetic polymorphism of the angiotensin converting enzyme and L-dopa-induced adverse effects in Parkinson's disease. J. Neurol. Sci. 2007, 252:130-134.
34. Lopez-Real A., Rey P., Soto-Otero R., Mendez-Alvarez E., Labandeira-Garcia J.L. Angiotensin-converting enzyme inhibition reduces oxidative stress and protects dopaminergic neurons in a 6-hydroxydopamine rat model of Parkinsonism. J. Neurosci. Res. 2005, 81:865-873.
35. Marchesi C., Paradis P., Schiffrin E.L. Role of the renin-angiotensin system in vascular inflammation. Trends Pharmacol. Sci. 2008, 29:367-374.
36. McKinley M.J., Albiston A.L., Allen A.M., Mathai M.L., May C.N., McAllen R.M., Oldfield B.J., Mendelsohn F.A., Chai S.Y., Mendelsohn F.A.O. The brain renin-angiotensin system: location and physiological roles. Int. J. Biochem. Cell Biol. 2003, 35:901-918.
37. Meredith G.E., Sonsalla P.K., Chesselet M.-F. Animal models of Parkinson's disease progression. Acta Neuropathol. 2008, 115:385-398.
38. Mertens B., Massie A., Michotte Y., Sarre S. Effect of nigrostriatal damage induced by 6-hydroxydopamine on the expression of glial cell line-derived neurotrophic factor in the striatum of the rat. Neuroscience 2009, 162:148-154.
39. Milsted A., Barna B.P., Ransohoff R.M., Brosnihan K.B., Ferrario C.M. Astrocyte cultures derived from human brain tissue express angiotensinogen mRNA. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:5720-5723.
40. Munoz A., Rey P., Guerra M.J., Mendez-Alvarez E., Soto-Otero R., Labandeira-Garcia J.L. Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism. Neuropharmacology 2006, 51:112-120.
41. Nomura D.K., Morrison B.E., Blankman J.L., Long J.Z., Kinsey S.G., Marcondes M.C.G., Ward A.M., Hahn Y.K., Lichtman A.H., Conti B., Cravatt B.F. Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science 2011, 334:809-813.
42. Ochi M., Shiozaki S., Kase H. Adenosine A(2A) receptor-mediated modulation of GABA and glutamate release in the output regions of the basal ganglia in a rodent model of Parkinson's disease. Neuroscience 2004, 127:223-231.
43. Paxinos G., Watson C. The Rat Brain in Steriotaxic Coordinates 1986, Academic Press, Orlando, FL.
44. Pickrell A.M., Pinto M., Hida A., Moraes C.T. Striatal dysfunctions associated with mitochondrial DNA damage in dopaminergic neurons in a mouse model of Parkinson's disease. J. Neurosci. 2011, 31:17649-17658.
45. Pierri M., Vaudano E., Sager T., Englund U. KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse. Neuropharmacology 2005, 48:517-524.
46. Reardon K.A., Mendelsohn F.A., Chai S.Y., Horne M.K. The angiotensin converting enzyme (ACE) inhibitor, perindopril, modifies the clinical features of Parkinson's disease. Aust. N. Z. J. Med. 2000, 30:48-53.
47. Rodriguez-Pallares J., Rey P., Parga J.A., Munoz A., Guerra M.J., Labandeira-Garcia J.L. Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS. Neurobiol. Dis. 2008, 31:58-73.
48. Rodriguez-Perez A.I., Valenzuela R., Villar-Cheda B., Guerra M.J., Lanciego J.L., Labandeira-Garcia J.L. Estrogen and angiotensin interaction in the substantia nigra. Relevance to postmenopausal Parkinson's disease. Exp. Neurol. 2010, 224:517-526.
49. Rodriguez-Perez A.I., Valenzuela R., Villar-Cheda B., Guerra M.J., Labandeira-Garcia J.L. Dopaminergic neuroprotection of hormonal replacement therapy in young and aged menopausal rats: role of the brain angiotensin system. Brain 2012, 135:124-138.
50. Saavedra J.M. Angiotensin II AT(1) receptor blockers ameliorate inflammatory stress: a beneficial effect for the treatment of brain disorders. Cell. Mol. Neurobiol. 2012, 32:667-681.
51. Saavedra J.M., Benicky J., Zhou J. Mechanisms of the Anti-ischemic effect of angiotensin II AT(1) receptor antagonists in the brain. Cell. Mol. Neurobiol. 2006, 26:1099-1111.
52. Sanchez-Lemus E., Benicky J., Pavel J., Saavedra J.M. In vivo Angiotensin II AT1 receptor blockade selectively inhibits LPS-induced innate immune response and ACTH release in rat pituitary gland. Brain Behav. Evol. 2009, 23:945-957.
53. Schapira A.H.V. Mitochondrial diseases. Lancet 2012, 379:1825-1834.
54. Schintu N., Frau L., Ibba M., Caboni P., Garau A., Carboni E., Carta A.R. PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease. Eur. J. Neurosci. 2009, 29:954-963.
55. Schulz R., Heusch G. Angiotensin II type 1 receptors in cerebral ischaemia-reperfusion: initiation of inflammation. J. Hypertens. Suppl. 2006, 24:S123-S129.
56. Schwager S.L., Carmona A.K., Sturrock E.D. A high-throughput fluorimetric assay for angiotensin I-converting enzyme. Nat. Protoc. 2006, 1:1961-1964.
57. Sonsalla P.K., Wong L.-Y., Harris S.L., Richardson J.R., Khobahy I., Li W., Shrikanth B., German D.G. Caffeine treatment prevents nigral dopamine neuron loss in a progressive rat model of Parkinson's disease. Exp. Neurol. 2012, 234:482-487.
58. Vyas I., Heikkila R.E., Nicklas W.J. Studies on the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: inhibition of NAD-linked substrate oxidation by its metabolite, 1-methyl-4-phenylpyridinium. J. Neurochem. 1986, 46:1501-1507.
59. Wu X., Kihara T., Hongo H., Akaike A., Niidome T., Sugimoto H. Angiotensin receptor type 1 antagonists protect against neuronal injury induced by oxygen-glucose depletion. Br. J. Pharmacol. 2010, 161:33-50.
60. Yazdani U., German D.C., Liang C.L., Manzino L., Sonsalla P.K., Zeevalk G.D. Rat model of Parkinson's disease: chronic central delivery of 1-methyl-4-phenylpyridinium (MPP+). Exp. Neurol. 2006, 200:172-183.
61. Yu L., Shen H.-Y., Coelho J.E., Araujo I.M., Huang Q.-Y., Day Y.-J., Rebola N., Canas P.M., Rapp E.K., Ferrara J., Taylor D., Muller C.E., Linden J., Cunha R.A., Chen J.-F. Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms. Ann. Neurol. 2008, 63:338-346.
62. Zeevalk G.D., Manzino L., Sonsalla P.K. NMDA receptors modulate dopamine loss due to energy impairment in the substantia nigra but not striatum. Exp. Neurol. 2000, 161:638-646.
63. Zeevalk G.D., Manzino L., Sonsalla P.K., Bernard L.P. Characterization of intracellular elevation of glutathione (GSH) with glutathione monoethyl ester and GSH in brain and neuronal cultures: relevance to Parkinson's disease. Exp. Neurol. 2007, 203:512-520.